On Thursday, Shares of Youku Tudou Inc. (NYSE:YOKU), lost -0.07% to $27.
Youku Tudou Inc (ADR) (NYSE:YOKU) stands at the average volume of 3,502,830 with the total number of shares traded on the last trading day was 1,221,912. The stock closed at $27 after declining -0.07%. The opening price on the last trading day for the stock was $26.97. Its market capitalization is $5.28B with the total number of shares held by investors. Its 52-week range is $11.85 - $31.50.
Youku Tudou Inc. operates as an Internet television company in the People’s Republic of China. Its Internet television platform enables users to search, view, and share video content across various devices. The company’s services for users comprise online video content library comprising primarily of professionally produced content, counting television serial dramas, movies, current event reports, variety shows, and music videos.
Shares of Discovery Communications, Inc. (NASDAQ:DISCK), declined -0.37% to $27.19, during its last trading session.
Discovery Communications, will report full year and fourth quarter 2015 results on Thursday, February 18, 2016, at 7:00 a.m. ET. The company will host a conference call at 8:30 a.m. ET to discuss the results.
Discovery Communications, Inc. operates as a media company. The company operates through U.S. Networks; International Networks; and Education and Other segments. The company owns and operates television networks under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids.
Finally, Array BioPharma Inc. (NASDAQ:ARRY), ended its last trade with 0.65% gain, and closed at $3.85. Array BioPharma stock price is predictable to reach $ 10.33 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $14 while the lower estimate is at $8. The standard deviation of the price stands at $2.5.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur